US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Maze Therapeutics

29.60

+0.17000.58%

Post-market: 29.600.00000.00%19:30 EDT

Volume:282.29K

Turnover:8.31M

Market Cap:1.64B

PE:-11.76

High:29.76

Open:29.27

Low:28.33

Close:29.43

52wk High:53.65

52wk Low:12.91

Shares:55.25M

Float Shares:37.25M

Volume Ratio:0.76

T/O Rate:0.76%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5172

EPS(LYR):-3.0510

ROE:-37.35%

ROA:-21.79%

PB:3.61

PE(LYR):-9.70

Loading ...

Overview Company News Filings

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Press Release: MindMaze Therapeutics Completes Organizational Simplification and Provides Update on Neuro.io Equity Financing

Maze Therapeutics CEO Jason V. Coloma Reports Sale of Common Shares Worth $921,153

Maze Therapeutics CSBO Atul Dandekar Disposes of 7,500 Common Shares Worth $204,859.44

Maze Therapeutics (MAZE) Stock Looks Fully Priced After A 59% Gain##

Simply Wall St.

Maze Therapeutics Advances MZE782 Phase 2 PKU Trial, Setting Up a New Catalyst for MAZE Investors

Maze Therapeutics CEO Jason V. Coloma Disposes of 34,501 Common Shares Worth $1.03 Million

Maze Therapeutics CSBO Atul Dandekar Disposes of $210,150 in Common Shares

Maze Therapeutics CEO Jason V. Coloma Sells USD 723,021 in Common Shares

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS)

Maze Therapeutics Shareholders Elect Directors, Ratify Auditor

Maze Therapeutics shareholders elect Coloma, Kumar as directors at annual meeting

Maze Therapeutics CEO Jason V. Coloma sells 6,643 shares worth $174,171.83

Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of common shares worth $381,499.47

Maze Therapeutics posts corporate presentation on genetics-driven kidney, metabolic disease drug pipeline

Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares for $197,554‬

Maze Therapeutics CEO Jason V. Coloma disposes of 32,564 common shares worth $846,980.45

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

J.P. Morgan Keeps Their Buy Rating on Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics CFO Expands Role Amid Finance Leadership Change

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/MAZE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MAZE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":29.6,"timestamp":1787601600000,"preClose":29.43,"halted":0,"volume":282286,"hourTrading":{"tag":"盘后","latestPrice":29.6,"preClose":29.6,"latestTime":"19:30 EDT","volume":4913,"amount":145383.5,"timestamp":1787614207230,"change":0,"changeRate":0,"amplitude":0.007432},"delay":0,"changeRate":0.005776418620455376,"floatShares":37250300,"shares":55248700,"eps":-2.517242,"marketStatus":"Not Yet Opened","change":0.17,"latestTime":"08-24 16:00:00 EDT","open":29.27,"high":29.76,"low":28.3339,"amount":8307856.231609999,"amplitude":0.048457,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.517242,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":0,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":29.43,"preHourTrading":{"tag":"盘前","latestPrice":29.31,"preClose":29.43,"latestTime":"09:29 EDT","volume":106,"amount":3108.0000299999997,"timestamp":1787578199993,"change":-0.12,"changeRate":-0.004077,"amplitude":0.006456},"postHourTrading":{"tag":"盘后","latestPrice":29.6,"preClose":29.6,"latestTime":"19:30 EDT","volume":4913,"amount":145383.5,"timestamp":1787614207230,"change":0,"changeRate":0,"amplitude":0.007432},"volumeRatio":0.759428,"impliedVol":1.032,"impliedVolPercentile":0.8298},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","floatShares":37250300,"roa":"-21.79%","roe":"-37.35%","lyrEps":-3.051003,"volumeRatio":0.759428,"shares":55248700,"dividePrice":0,"high":29.76,"amplitude":0.048457,"preClose":29.43,"low":28.3339,"week52Low":12.91,"pbRate":"3.61","psRate":"81.77","week52High":53.65,"institutionHeld":0,"latestPrice":29.6,"eps":-2.517242,"divideRate":0,"volume":282286,"delay":0,"ttmEps":-2.517242,"open":29.27,"prevYearClose":41.43,"prevWeekClose":29.43,"prevMonthClose":26.92,"prevQuarterClose":29.84,"fiveDayClose":27.95,"twentyDayClose":28.69,"sixtyDayClose":26.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MAZE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"MAZE","fiscalQuarterEnding":"2026/06","expectedEps":-0.76,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-0.76},{"market":"US","date":"2026-05-12","symbol":"MAZE","fiscalQuarterEnding":"2026/03","expectedEps":-0.43,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.45},{"market":"US","date":"2026-03-25","symbol":"MAZE","fiscalQuarterEnding":"2025/12","expectedEps":-0.73,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774411200000,"reportTimeType":"pre","actualEps":-0.65},{"market":"US","date":"2025-11-06","symbol":"MAZE","fiscalQuarterEnding":"2025/09","expectedEps":-0.74,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-08-12","symbol":"MAZE","fiscalQuarterEnding":"2025/06","expectedEps":-0.79,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.77}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MAZE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MAZE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4167,"buy":0.5833,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1773979200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MAZE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MAZE","date":"2026-08-21","current":-11.758901,"percent":0.328205,"low":-19.775245,"twenty":-14.610658,"median":-10.685878,"eighty":9.273272,"high":14.99285,"avg":-4.856742,"sd":11.100913,"marketCap":1607037430},"quantilePoints":[{"date":"2025-01-31","current":12.681398,"twenty":12.46124,"median":12.543799,"eighty":12.626358,"marketCap":700431648},{"date":"2025-02-07","current":10.303636,"twenty":10.343265,"median":11.88881,"eighty":12.594654,"marketCap":569100714},{"date":"2025-02-14","current":8.972089,"twenty":9.94063,"median":10.40271,"eighty":12.302722,"marketCap":495555390},{"date":"2025-02-21","current":9.645788,"twenty":9.645788,"median":10.220414,"eighty":11.88881,"marketCap":532765822},{"date":"2025-02-28","current":10.081711,"twenty":9.495197,"median":10.081711,"eighty":10.604819,"marketCap":556843160},{"date":"2025-03-07","current":9.29705,"twenty":9.29705,"median":9.788453,"eighty":10.501783,"marketCap":513503951},{"date":"2025-03-14","current":8.956237,"twenty":8.972089,"median":9.582381,"eighty":10.303636,"marketCap":494679851},{"date":"2025-03-21","current":9.479345,"twenty":8.972089,"median":9.534826,"eighty":10.271932,"marketCap":523572656},{"date":"2025-03-28","current":8.93246,"twenty":8.956237,"median":9.495197,"eighty":10.168896,"marketCap":493366542},{"date":"2025-04-04","current":7.814885,"twenty":8.89283,"median":9.443679,"eighty":10.137192,"marketCap":408179251},{"date":"2025-04-11","current":6.372653,"twenty":8.695317,"median":9.384234,"eighty":10.081711,"marketCap":332850033},{"date":"2025-04-17","current":6.858987,"twenty":8.362362,"median":9.29705,"eighty":9.98026,"marketCap":358251746},{"date":"2025-04-25","current":6.456504,"twenty":7.783022,"median":9.224877,"eighty":9.897831,"marketCap":337229638},{"date":"2025-05-02","current":8.879789,"twenty":7.580103,"median":8.972089,"eighty":9.731387,"marketCap":463800243},{"date":"2025-05-09","current":8.40184,"twenty":7.63209,"median":8.956237,"eighty":9.655299,"marketCap":438836491},{"date":"2025-05-16","current":7.799992,"twenty":7.63958,"median":8.89283,"eighty":9.626766,"marketCap":405123785},{"date":"2025-05-23","current":8.575775,"twenty":7.65241,"median":8.850167,"eighty":9.590307,"marketCap":445417178},{"date":"2025-05-30","current":10.26226,"twenty":7.715941,"median":8.87535,"eighty":9.631522,"marketCap":533011510},{"date":"2025-06-06","current":11.248853,"twenty":7.782471,"median":8.89283,"eighty":9.769431,"marketCap":584254194},{"date":"2025-06-13","current":11.425934,"twenty":7.799992,"median":8.956237,"eighty":10.149874,"marketCap":593451599},{"date":"2025-06-20","current":9.494909,"twenty":7.805949,"median":9.034945,"eighty":10.238649,"marketCap":493156089},{"date":"2025-06-27","current":10.742908,"twenty":7.871903,"median":9.097801,"eighty":10.238649,"marketCap":557975894},{"date":"2025-07-03","current":9.697287,"twenty":7.967493,"median":9.217791,"eighty":10.255514,"marketCap":503667409},{"date":"2025-07-11","current":13.188311,"twenty":8.01948,"median":9.285161,"eighty":10.297295,"marketCap":684987676},{"date":"2025-07-18","current":14.385715,"twenty":8.08904,"median":9.384234,"eighty":10.584212,"marketCap":747179651},{"date":"2025-07-25","current":13.871337,"twenty":8.197097,"median":9.417731,"eighty":10.84241,"marketCap":720463380},{"date":"2025-08-01","current":12.437825,"twenty":8.267679,"median":9.479345,"eighty":11.289329,"marketCap":646008198},{"date":"2025-08-08","current":11.231989,"twenty":8.274387,"median":9.503122,"eighty":11.660356,"marketCap":583378251},{"date":"2025-08-15","current":-4.846264,"twenty":8.197097,"median":9.495197,"eighty":11.50014,"marketCap":585409301},{"date":"2025-08-22","current":-4.802702,"twenty":7.843394,"median":9.46183,"eighty":11.412442,"marketCap":580147195},{"date":"2025-08-29","current":-5.180239,"twenty":7.675693,"median":9.408012,"eighty":11.34667,"marketCap":625752114},{"date":"2025-09-05","current":-5.459761,"twenty":7.605258,"median":9.384234,"eighty":11.299448,"marketCap":659517295},{"date":"2025-09-12","current":-9.002797,"twenty":7.051844,"median":9.285161,"eighty":11.248853,"marketCap":1087501923},{"date":"2025-09-19","current":-8.523616,"twenty":6.791906,"median":9.217791,"eighty":11.231989,"marketCap":1029618756},{"date":"2025-09-26","current":-9.565472,"twenty":6.372653,"median":9.072896,"eighty":11.223556,"marketCap":1155470793},{"date":"2025-10-03","current":-9.619925,"twenty":-4.846264,"median":8.956237,"eighty":11.080205,"marketCap":1162048426},{"date":"2025-10-10","current":-10.440341,"twenty":-4.897086,"median":8.912645,"eighty":10.903124,"marketCap":1261151423},{"date":"2025-10-17","current":-10.327806,"twenty":-5.035032,"median":8.87091,"eighty":10.852529,"marketCap":1247557649},{"date":"2025-10-24","current":-10.854179,"twenty":-5.43435,"median":8.743704,"eighty":10.801935,"marketCap":1311141431},{"date":"2025-10-31","current":-12.059392,"twenty":-5.764695,"median":8.710535,"eighty":10.776638,"marketCap":1456726366},{"date":"2025-11-07","current":-10.301208,"twenty":-8.440123,"median":8.622163,"eighty":10.742908,"marketCap":1299301692},{"date":"2025-11-14","current":-12.147078,"twenty":-8.530877,"median":8.52824,"eighty":10.604819,"marketCap":1532123096},{"date":"2025-11-21","current":-13.570087,"twenty":-9.148004,"median":8.467465,"eighty":10.501783,"marketCap":1711608623},{"date":"2025-11-28","current":-14.401765,"twenty":-9.516102,"median":8.389744,"eighty":10.458575,"marketCap":1816509011},{"date":"2025-12-05","current":-16.252058,"twenty":-9.864597,"median":8.267679,"eighty":10.366822,"marketCap":2049888314},{"date":"2025-12-12","current":-15.096102,"twenty":-10.151143,"median":8.122944,"eighty":10.312226,"marketCap":1904086399},{"date":"2025-12-19","current":-15.496681,"twenty":-10.373183,"median":7.957431,"eighty":10.278273,"marketCap":1954611815},{"date":"2025-12-26","current":-16.053676,"twenty":-10.591356,"median":7.799992,"eighty":10.266129,"marketCap":2024866203},{"date":"2026-01-02","current":-15.805699,"twenty":-10.832398,"median":7.756189,"eighty":10.248768,"marketCap":1993588564},{"date":"2026-01-09","current":-14.859569,"twenty":-11.164921,"median":7.639287,"eighty":10.225157,"marketCap":1874252343},{"date":"2026-01-16","current":-15.187663,"twenty":-11.722514,"median":7.479482,"eighty":10.213352,"marketCap":1915635065},{"date":"2026-01-23","current":-17.625471,"twenty":-12.065201,"median":7.127309,"eighty":10.196366,"marketCap":2223118312},{"date":"2026-01-30","current":-17.167667,"twenty":-12.419472,"median":6.955415,"eighty":10.162555,"marketCap":2165374980},{"date":"2026-02-06","current":-16.767088,"twenty":-13.567798,"median":6.791906,"eighty":10.126096,"marketCap":2114849563},{"date":"2026-02-13","current":-17.945934,"twenty":-14.175152,"median":6.511006,"eighty":10.056348,"marketCap":2263538645},{"date":"2026-02-20","current":-17.182927,"twenty":-14.401765,"median":6.360075,"eighty":9.954897,"marketCap":2167299757},{"date":"2026-02-27","current":-17.48813,"twenty":-14.737488,"median":-4.831743,"eighty":9.883564,"marketCap":2205795312},{"date":"2026-03-06","current":-17.282118,"twenty":-15.149512,"median":-4.864415,"eighty":9.832206,"marketCap":2179810813},{"date":"2026-03-13","current":-19.775245,"twenty":-15.332634,"median":-4.897086,"eighty":9.697287,"marketCap":2494271379},{"date":"2026-03-20","current":-18.857728,"twenty":-15.469975,"median":-4.962429,"eighty":9.697287,"marketCap":2378544116},{"date":"2026-03-27","current":-12.021519,"twenty":-15.550091,"median":-5.100375,"eighty":9.693343,"marketCap":1576261545},{"date":"2026-04-02","current":-11.013091,"twenty":-15.507363,"median":-5.260102,"eighty":9.683007,"marketCap":1444036514},{"date":"2026-04-10","current":-10.569535,"twenty":-15.475316,"median":-5.486987,"eighty":9.652715,"marketCap":1385877385},{"date":"2026-04-17","current":-10.186635,"twenty":-15.415039,"median":-5.764695,"eighty":9.626766,"marketCap":1335671640},{"date":"2026-04-24","current":-10.959561,"twenty":-15.395201,"median":-7.129635,"eighty":9.621519,"marketCap":1437017594},{"date":"2026-05-01","current":-11.209856,"twenty":-15.384518,"median":-8.456458,"eighty":9.590184,"marketCap":1469836362},{"date":"2026-05-08","current":-10.741725,"twenty":-15.342553,"median":-8.527247,"eighty":9.573739,"marketCap":1408454934},{"date":"2026-05-15","current":-11.93693,"twenty":-15.289905,"median":-9.002797,"eighty":9.561199,"marketCap":1462775248},{"date":"2026-05-22","current":-11.629812,"twenty":-15.205975,"median":-9.258724,"eighty":9.520559,"marketCap":1425140470},{"date":"2026-05-29","current":-11.92338,"twenty":-15.178506,"median":-9.458383,"eighty":9.511048,"marketCap":1461114890},{"date":"2026-06-05","current":-11.471737,"twenty":-15.158668,"median":-9.619925,"eighty":9.501537,"marketCap":1405769629},{"date":"2026-06-12","current":-10.880085,"twenty":-15.117466,"median":-9.821399,"eighty":9.495024,"marketCap":1333267337},{"date":"2026-06-18","current":-11.218817,"twenty":-15.001489,"median":-9.973866,"eighty":9.488683,"marketCap":1374776283},{"date":"2026-06-26","current":-12.203399,"twenty":-14.845835,"median":-10.113627,"eighty":9.465333,"marketCap":1495428952},{"date":"2026-07-02","current":-13.463484,"twenty":-14.807685,"median":-10.175262,"eighty":9.440942,"marketCap":1649842230},{"date":"2026-07-10","current":-14.642273,"twenty":-14.807685,"median":-10.243922,"eighty":9.423562,"marketCap":1794293361},{"date":"2026-07-17","current":-12.268888,"twenty":-14.735962,"median":-10.345957,"eighty":9.406427,"marketCap":1503454015},{"date":"2026-07-24","current":-12.506,"twenty":-14.713835,"median":-10.387794,"eighty":9.396916,"marketCap":1532510277},{"date":"2026-07-31","current":-12.478902,"twenty":-14.649742,"median":-10.467027,"eighty":9.384234,"marketCap":1529189561},{"date":"2026-08-07","current":-12.88538,"twenty":-14.642273,"median":-10.571027,"eighty":9.336679,"marketCap":1579000296},{"date":"2026-08-14","current":-11.503614,"twenty":-14.638297,"median":-10.649147,"eighty":9.29705,"marketCap":1536767732},{"date":"2026-08-21","current":-12.029624,"twenty":-14.610658,"median":-10.685878,"eighty":9.273272,"marketCap":1607037430}],"updateTime":1787643315699},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MAZE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658945835","title":"Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945835","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945835?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:01","pubTimestamp":1786478460,"startTime":"0","endTime":"0","summary":"Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3343141/0/en/maze-therapeutics-reports-second-quarter-2026-financial-results-and-recent-highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","FSGS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658079816","title":"Press Release: MindMaze Therapeutics Completes Organizational Simplification and Provides Update on Neuro.io Equity Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658079816","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658079816?lang=en_us&edition=fundamental","pubTime":"2026-08-10 13:29","pubTimestamp":1786339740,"startTime":"0","endTime":"0","summary":"GENEVA, Aug. 10, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today provided updat","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REZ","BK4588","BK4007","BK4215","EQR","VMRK","MAZE","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657520619","title":"Maze Therapeutics CEO Jason V. Coloma Reports Sale of Common Shares Worth $921,153","url":"https://stock-news.laohu8.com/highlight/detail?id=2657520619","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657520619?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:10","pubTimestamp":1785960615,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CEO Jason V. Coloma reports sale of common shares worth $921,153Maze Therapeutics CEO Jason V. Coloma sold 34,501 common shares on Aug. 3, 2026 at about $26.71–$27.09 each.Sales were","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL5mXV3C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CEO Jason V. Coloma Reports Sale of Common Shares Worth $921,153","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656399196","title":"Maze Therapeutics CSBO Atul Dandekar Disposes of 7,500 Common Shares Worth $204,859.44","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399196","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656399196?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:16","pubTimestamp":1785528987,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares worth $204,859.44Maze Therapeutics CSBO Atul Dandekar exercised options for 7,500 shares at USD 10.42 on July 29, 2026.He sold 7,50","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL2jSdyV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CSBO Atul Dandekar Disposes of 7,500 Common Shares Worth $204,859.44","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652284332","title":"Maze Therapeutics (MAZE) Stock Looks Fully Priced After A 59% Gain##","url":"https://stock-news.laohu8.com/highlight/detail?id=2652284332","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652284332?lang=en_us&edition=fundamental","pubTime":"2026-07-17 22:20","pubTimestamp":1784298025,"startTime":"0","endTime":"0","summary":"Maze Therapeutics stock has delivered a strong 59.2% return over the past year, yet its low value score and an overvalued read on market multiples suggest investors are paying up without a clear margin of safety.\n\nOver the last 12 months, Maze Therapeutics has returned 59.2%, which puts the spotlight on whether recent gains already reflect much of the good news investors expect.\nFuture progress in turning its pipeline into consistent, scalable cash flows can support the current share price,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-maze/maze-therapeutics/news/maze-therapeutics-maze-stock-looks-fully-priced-after-a-59-g","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-maze/maze-therapeutics/news/maze-therapeutics-maze-stock-looks-fully-priced-after-a-59-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MAZE","TSPA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651488864","title":"Maze Therapeutics Advances MZE782 Phase 2 PKU Trial, Setting Up a New Catalyst for MAZE Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2651488864","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651488864?lang=en_us&edition=fundamental","pubTime":"2026-07-15 00:31","pubTimestamp":1784046697,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. ($MAZE) announced an update on their ongoing clinical study. The Phase 2 study “A Phase 2, Randomized, Double-blind, Placeb...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-advances-mze782-phase-2-pku-trial-setting-up-a-new-catalyst-for-maze-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-advances-mze782-phase-2-pku-trial-setting-up-a-new-catalyst-for-maze-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","BK4007","MAZE","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648863335","title":"Maze Therapeutics CEO Jason V. Coloma Disposes of 34,501 Common Shares Worth $1.03 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2648863335","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648863335?lang=en_us&edition=fundamental","pubTime":"2026-07-03 04:29","pubTimestamp":1783024191,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CEO Jason V. Coloma disposes of 34,501 common shares worth $1.03 millionMaze Therapeutics CEO Jason V. Coloma sold 34,501 shares of common stock on July 1.Sales prices averaged about","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL42GkCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CEO Jason V. Coloma Disposes of 34,501 Common Shares Worth $1.03 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648526615","title":"Maze Therapeutics CSBO Atul Dandekar Disposes of $210,150 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2648526615","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648526615?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:18","pubTimestamp":1782937087,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CSBO Atul Dandekar disposes of $210,150 in common sharesMaze Therapeutics CSBO Atul Dandekar exercised stock options for 7,500 shares at USD 10.42 on June 29, 2026.Dandekar sold 7,50","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL3bsslX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CSBO Atul Dandekar Disposes of $210,150 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646459568","title":"Maze Therapeutics CEO Jason V. Coloma Sells USD 723,021 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2646459568","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646459568?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:15","pubTimestamp":1782332157,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CEO Jason V. Coloma sells USD 723,021 in common sharesMaze Therapeutics CEO Jason V. Coloma reported sales of 27,858 common shares on June 22-23.Shares sold at weighted average price","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL4PsQVf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CEO Jason V. Coloma Sells USD 723,021 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029997","title":"Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029997?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:46","pubTimestamp":1782125207,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-maze-therapeutics-inc-maze-and-universal-health-uhs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-maze-therapeutics-inc-maze-and-universal-health-uhs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","ZYME","XLV","MAZE","BK4139","BK4581","UHS","HCSG","XBI","BK4585","BK4007","BK4185","LU0128526141.USD","LU0029874061.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642627471","title":"Maze Therapeutics Shareholders Elect Directors, Ratify Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2642627471","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642627471?lang=en_us&edition=fundamental","pubTime":"2026-06-11 06:07","pubTimestamp":1781129256,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Maze Therapeutics, Inc. ( ($MAZE) ). On June 8, 2026, Maze Therapeutics, Inc. held its 2026 annual meeting of s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-shareholders-elect-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-shareholders-elect-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642734475","title":"Maze Therapeutics shareholders elect Coloma, Kumar as directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642734475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642734475?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:16","pubTimestamp":1781122595,"startTime":"0","endTime":"0","summary":"Maze Therapeutics held its annual shareholder meeting on June 8, 2026.Stockholders chose Jason Coloma and Neil Kumar to serve as Class I directors through the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL6WVkM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640918476","title":"Maze Therapeutics CEO Jason V. Coloma sells 6,643 shares worth $174,171.83","url":"https://stock-news.laohu8.com/highlight/detail?id=2640918476","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640918476?lang=en_us&edition=fundamental","pubTime":"2026-06-04 05:04","pubTimestamp":1780520689,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CEO Jason V. Coloma sold 6,643 shares of common stock on June 1.Shares sold at weighted average prices of $26.2 and $26.24.Holdings fell to 344,897 shares in the Coloma Family Trust; 27,970 shares in The Coloma 2021 Irrevocable Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL9YjWt6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CEO Jason V. Coloma sells 6,643 shares worth $174,171.83","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640118420","title":"Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of common shares worth $381,499.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2640118420","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640118420?lang=en_us&edition=fundamental","pubTime":"2026-06-04 05:02","pubTimestamp":1780520539,"startTime":"0","endTime":"0","summary":"Sales priced at USD 25.57 and USD 26.36; holdings fell to zero shares.He exercised stock options for 14,853 shares at USD 10.42 in the same session.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDLcbqklh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of common shares worth $381,499.47","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640906737","title":"Maze Therapeutics posts corporate presentation on genetics-driven kidney, metabolic disease drug pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2640906737","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640906737?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:10","pubTimestamp":1780485039,"startTime":"0","endTime":"0","summary":"Maze Therapeutics outlined a kidney and metabolic disease pipeline, led by MZE829, a selective APOL1 inhibitor for APOL1-mediated kidney disease.Phase 2 HORIZON initial data showed a 36% mean uACR reduction across 12 evaluable patients; 50% achieved at least a 30% reduction.Non-diabetic patients showed a 49% mean uACR reduction; the FSGS subset showed a 62% mean reduction, supporting plans for a pivotal program.Additional HORIZON data targeted for late 2026 or early 2027; pivotal trial initiation targeted for 1H 2027, subject to regulatory feedback.Cash runway expected into 2029 under the current business plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this new","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL8W3B5w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640230549","title":"Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares for $197,554‬","url":"https://stock-news.laohu8.com/highlight/detail?id=2640230549","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640230549?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:12","pubTimestamp":1780431176,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CSBO Atul Dandekar sold 7,500 common shares on May 29 at USD 26.34.The sale followed the exercise of 7,500 stock options at USD 10.42.Dandekar ended the day with 24,808 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDLNYsKv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares for $197,554‬","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638357086","title":"Maze Therapeutics CEO Jason V. Coloma disposes of 32,564 common shares worth $846,980.45","url":"https://stock-news.laohu8.com/highlight/detail?id=2638357086","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638357086?lang=en_us&edition=fundamental","pubTime":"2026-05-28 04:17","pubTimestamp":1779913063,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CEO Jason V. Coloma disclosed sales of 32,564 common shares at about USD 26 per share on May 22 and May 26.The shares were sold from trusts in which Coloma reports indirect beneficial ownership.Holdings reported after the sales were 350,987 shares in the Coloma Family Trust and 28,523 shares in The Coloma 2021 Irrevocable Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL9Qv1F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CEO Jason V. Coloma disposes of 32,564 common shares worth $846,980.45","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638049545","title":"Maze Therapeutics to Participate in Two Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2638049545","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638049545?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:03","pubTimestamp":1779879780,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., May  27, 2026  (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301796/0/en/Maze-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637032299","title":"J.P. Morgan Keeps Their Buy Rating on Maze Therapeutics, Inc. (MAZE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637032299","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637032299?lang=en_us&edition=fundamental","pubTime":"2026-05-23 20:15","pubTimestamp":1779538559,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Anupam Rama maintained a Buy rating on Maze Therapeutics, Inc. yesterday and set a price target of $53.00. The company’s shares...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-keeps-their-buy-rating-on-maze-therapeutics-inc-maze-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-keeps-their-buy-rating-on-maze-therapeutics-inc-maze-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637834057","title":"Maze Therapeutics CFO Expands Role Amid Finance Leadership Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2637834057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637834057?lang=en_us&edition=fundamental","pubTime":"2026-05-23 07:27","pubTimestamp":1779492423,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. ( ($MAZE) ) just unveiled an announcement. On May 18, 2026, Maze Therapeutics, Inc. announced that Senior Vice President of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-cfo-expands-role-amid-finance-leadership-change?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-cfo-expands-role-amid-finance-leadership-change?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":120,"code":"91000000","status":"200"}]}}